BLCO is the ticker symbol for Bausch & Lomb Corp, a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks BLCO with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is BLCO a good stock to buy?

13F Pro's AI ranking engine scores BLCO at 51.2/100, ranked #1,549 of 2,961 stocks based on 32 fundamental signals including profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for BLCO is available at https://13fpro.ai/company/BLCO. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source BLCO data?

All Bausch & Lomb Corp fundamentals and ownership data come directly from SEC EDGAR. Bausch & Lomb Corp files with the SEC under CIK 1860742. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Bausch & Lomb Corp(BLCO)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Bausch & Lomb Corp (BLCO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BLCO at 51.2/100 on a 32-signal composite quality model, placing it at rank #1,549 of 2,961 stocks — the bottom half of the AI-ranked universe. BLCO scores in the top quartile across earnings quality (88.2), revenue scale (78.7). Areas of concern include institutional flow (25.0) and balance sheet strength (30.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 33.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Bausch & Lomb Corp reports quarterly revenue of $1.4B, net income of $-14.0M, an operating margin of 5.9%. Top institutional holders of BLCO by reported 13-F value include ICAHN CARL C, OAKTREE CAPITAL MANAGEMENT, DEUTSCHE BANK AG\, based on the most recent SEC filings. BLCO trades on the NYSE exchange and files with the SEC under CIK 1860742. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BLCO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bausch & Lomb Corp directly from SEC EDGAR.

AI Quality Score

51.2/100

AI Rank

#1,549

Revenue

$1.4B

Net Income

$-14.0M

Free Cash Flow

$82.0M

Operating Margin

5.9%

BLCO key financials by period

Bausch & Lomb Corp reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	10-K	$5.1B	$-360.0M	2.2%
FY 2024	10-K	$4.8B	$-317.0M	3.4%
FY 2023	10-K	$4.1B	$-260.0M	3.1%
FY 2022	10-K	$3.8B	$6.0M	5.5%
FY 2021	10-K	$3.8B	$182.0M	8.7%
FY 2020	10-K	$3.4B	$-18.0M	7.6%

Institutions holding BLCO

Institutional investors reporting a position in Bausch & Lomb Corp on SEC Form 13F.
Institution	Shares	Value	Reported
ICAHN CARL C	3,500,000	$58.0M	2026-06-30
OAKTREE CAPITAL MANAGEMENT	3,441,042	$57.0M	2026-06-30
DEUTSCHE BANK AG\	3,423,046	$56.7M	2026-06-30
D. E. Shaw	3,323,021	$55.0M	2026-06-30
DAVIDSON KEMPNER CAPITAL MANAGEMENT	3,158,972	$52.3M	2026-06-30
GOLDENTREE ASSET MANAGEMENT	2,660,508	$44.0M	2026-06-30
PRICE T ROWE ASSOCIATES	2,161,232	$35.8M	2026-06-30
CASPIAN CAPITAL	1,999,043	$33.1M	2026-06-30
GLENVIEW CAPITAL MANAGEMENT	1,918,148	$31.8M	2026-06-30
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	1,364,980	$22.6M	2026-06-30